SOURCE: IO News Wire

IO News Wire

April 12, 2010 07:30 ET

(OTC: KKUR) Cancer Detection Method Gaining Acceptance in the Medical Community

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - April 12, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) recently announced the newest specifications on its CS300 Series Chromosomal Scanner.

ChromoCure's proprietary method of cancer detection, the "aneuploidy theory," was the focus of the 1st Conference of Aneuploidy and Cancer: Clinical and Experimental Aspects in Oakland, California. ( The "aneuploidy theory" reportedly "held its weight" and was proven relevant by several independent labs during the conference. This further liberates aneuploidy theory from the competing gene mutation theory.

The Company's proprietary Chromosomal Scanner systems have proven accurate and efficient in measuring the unique characteristics found in 100% of all cancers at all stages.

For more information, please visit

Other active stocks are Millipore Corporation (NYSE: MIL) Life Technologies Corp (NASDAQ: LIFE) and eTotalSource Inc (PINKSHEETS: ETLS)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information